IONS vs JBIO
IONS: Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies, transitioning into a commercial-stage biotech with a pipeline focused on neurology and cardiometabolic diseases. JBIO: A clinical-stage biotechnology company developing innovative therapies for autoimmune and inflammatory diseases.
Side-by-side fundamentals
| Metric | IONS | JBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $43.30 | $14.15 | |
| Market cap | $7.2B | $900M | |
| Net margin FY2025, SEC XBRL | -40.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -40.4% | n/a | |
| ROE FY2025, SEC XBRL | -78.0% | -38.3% | JBIO higher |
| ROA FY2025, SEC XBRL | -10.8% | -36.4% | IONS higher |
| Debt / equity as of 2026-09-02 | 4.35 | 0.00 | JBIO lower |
| Revenue growth (YoY) as of 2026-09-02 | -7.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 0.70 | 0.57 | |
| 1-year return as of 2026-10-08 close | -38.1% | +55.8% | JBIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.